Inmune Bio INMB
NASDAQ INMB
$2.32 +0.16 (+7.41%)
At close: Aug 21, 2026 · 4:00 PM EDT

Inmune Bio (INMB) Amortizatization of Intangibles (2021 - 2024)

Inmune Bio (INMB) posted Amortizatization of Intangibles of -$6000.0 for Q4 2024, up 95.42% sequentially from -$131000.0 in Q3 2024, and down 113.33% YoY from $45000.0 in Q1 2024.

Inmune Bio (INMB) Amortizatization of Intangibles (2021 - 2024) Analysis & Trends

Inmune Bio has reported Amortizatization of Intangibles for 4 years, with the latest figure at -$6000.0 in Q4 2024.

  • Quarterly Amortizatization of Intangibles fell 113.33% year-over-year to -$6000.0 in Q4 2024, while the trailing twelve-month figure through Dec 2024 was -$79000.0 (down 135.27% YoY) and the FY2024 annual result came in at -$79000.0, down 135.27% from the prior year.
  • Amortizatization of Intangibles improved to -$6000.0 in Q4 2024 per INMB's latest filing, from -$131000.0 in the prior quarter.
  • Over five years, Amortizatization of Intangibles peaked at $68000.0 in Q4 2022 and troughed at -$131000.0 in Q3 2024.
  • A 4-year average of $35285.7 and a median of $55000.0 in 2022 frame the typical range for Amortizatization of Intangibles.
  • The sharpest annual moves came in 2023 and 2024: Amortizatization of Intangibles grew 19.64% in 2023, then tumbled 342.59% in 2024.
  • Over 4 years, Amortizatization of Intangibles stood at $57000.0 in 2021, then rose by 19.3% to $68000.0 in 2022, then slumped by 33.82% to $45000.0 in 2023, then sank by 113.33% to -$6000.0 in 2024.
  • According to Business Quant data, Amortizatization of Intangibles over the past three periods registered -$6000.0, -$131000.0, and $24000.0 for Q4 2024, Q3 2024, and Q2 2024 respectively.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Amortizatization of Intangibles (Qtr)
1 Vertex Pharmaceuticals 139.13 Bn 131.28 Bn 2.84 Bn -
2 Regeneron Pharmaceuticals 85.77 Bn 77.77 Bn 3.93 Bn -
3 Argenx Se 64.64 Bn 59.46 Bn 1.37 Bn -
4 Moderna 58.29 Bn 53.16 Bn 52.00 Mn -
5 BeOne Medicines 41.92 Bn 36.82 Bn 1.53 Bn -
6 Alnylam Pharmaceuticals 31.58 Bn 28.28 Bn 992.69 Mn -
7 BioNTech SE 28.12 Bn 9.73 Bn 668.28 Mn -
8 Insmed 27.39 Bn 26.22 Bn 358.27 Mn 678,000.00
9 Royalty Pharma 27.27 Bn 26.43 Bn - -
10 Inmune Bio 61.59 Mn 43.18 Mn - -

Historic Data

Download Data
DateValue
Dec 31, 2024 -6,000.00
Dec 31, 2024 -6,000.00
Sep 30, 2024 -131,000.00
Sep 30, 2024 -131,000.00
Jun 30, 2024 24,000.00
Jun 30, 2024 24,000.00
Mar 31, 2024 34,000.00
Mar 31, 2024 34,000.00
Dec 31, 2023 45,000.00
Dec 31, 2023 45,000.00
Sep 30, 2023 54,000.00
Sep 30, 2023 54,000.00
Jun 30, 2023 58,000.00
Jun 30, 2023 58,000.00
Mar 31, 2023 67,000.00
Mar 31, 2023 67,000.00
Dec 31, 2022 68,000.00
Dec 31, 2022 68,000.00
Sep 30, 2022 58,000.00
Sep 30, 2022 58,000.00